FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, namely oncology, and may be used for treating cancer. That is ensured by the introduction of an antitumour agent containing 1-(3-C-ethinyl-β-D-ribopentofuranosyl)cytosine (ECyd) or its pharmaceutically acceptable salt into a patient by the continuous intravenous introduction at a dose of 1.30 to 8.56 mg/m2 at 1-(3-C-ethinyl-β-D-ribopentofuranosyl)cytosine for each period of introduction 2 to 336 hours.
EFFECT: method for the ECyd introduction into the patient provides a substantial therapeutic effect with provided prolonged patient's life ensured by the continuous therapy without manifested peripheral neurotoxicity caused by ECyd.
5 cl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED CHEMOTHERAPY | 2001 |
|
RU2284818C2 |
| COMBINED CHEMOTHERAPY | 2010 |
|
RU2587013C2 |
| COMBINED CHEMOTHERAPY | 2006 |
|
RU2429838C2 |
| METHOD FOR INTRODUCING EPOTILONE ANALOGS FOR TREATING CANCER CASES | 2002 |
|
RU2292202C2 |
| COMBINED APPLICATION OF ECTEINASCIDIN-743 AND PLATINUM-CONTAINING ANTI-TUMOUR COMPOUNDS | 2004 |
|
RU2391101C2 |
| NEW DERIVATIVES OF PEG | 2015 |
|
RU2697551C2 |
| COMBINATION OF TRIFLURIDINE/TIPIRACIL HYDROCHLORIDE, ANTITUMOR PLATINUM COMPLEX, AND MODULATOR OF CONTROL POINTS OF IMMUNE RESPONSE | 2018 |
|
RU2778887C2 |
| METHODS AND COMPOSITIONS FOR TREATING CANCER | 2009 |
|
RU2508116C2 |
| METHODS OF APPLYING (+)-1,4-DIHYDRO-7-[(3S, 4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(THIAZOLYL)-1,8-NAPHTHIRIDINE-3-CARBOXYLIC ACID FOR CANCER TREATMENT | 2006 |
|
RU2592231C2 |
| ANTICANCER THERAPY USING COMPOUNDS OF 3,5-DISUBSTITUTED BENZENE ALKYNYL AND PEMBROLIZUMAB | 2020 |
|
RU2822064C2 |
